In the near future, molecular definition will be more relevant to establish the best therapy; for example, IDH1-mutated AML could receive oral ivosidenib and subcutaneous or intravenous azacitidine, since in a recent phase III trial this treatment showed an impressive median OS of 24.0 months [29]. This evidence concerns the gene IDH1 and acute myeloid leukemia.